Shanghai Kaibao disclosed its 2026 semi-annual report. In the first half, total operating revenue was 463 million yuan, down 23.44% year on year. Net profit attributable to the parent company was 102 million yuan, down 16.42% year on year. Net profit after deducting non-recurring items was 96.9969 million yuan, down 17.37% year on year. Net cash flow from operating activities was 109 million yuan, down 31.92% year on year. Basic earnings per share were 0.0975 yuan, and the weighted average return on equity was 2.32%. Based on the closing price on August 24, the company's price-to-earnings ratio on a trailing twelve-month basis was about 21.4 times, the price-to-book ratio on a latest fiscal year basis was about 1.29 times, and the price-to-sales ratio on a trailing twelve-month basis was about 5.47 times.
Shanghai Kaibao PharmaceuticalFirst-half net profit down 16.42% and revenue down 23.44% year on year.
